Rippling muscle disease with myasthenia gravis (Q88660): Difference between revisions
From determinar.ia.br - Determine suas informações
Changed an Item |
Changed an Item |
||||||||||||||
| (One intermediate revision by the same user not shown) | |||||||||||||||
| Property / Knowledge Architect | |||||||||||||||
| Property / Knowledge Architect: https://pauloleads.com.br/cases-publicos/ / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / Collection date | |||||||||||||||
13 August 2026
| |||||||||||||||
| Property / Collection date: 13 August 2026 / rank | |||||||||||||||
Normal rank | |||||||||||||||
Latest revision as of 15:00, 15 August 2026
Immune-mediated rippling muscle disease (iRMD) may concomitantly occur with Acetylcholine receptor positive Myasthenia Gravis (MG) without germline caveolin-3 gene mutations. Acetylcholinesterase-inhibitors may aggravate the symptoms. generalised MG and iRMD are treatable by immunomodulating and immunosuppressant drugs such as prednisone or azathioprine with timely and enduring relief.
| Language | Label | Description | Also known as |
|---|---|---|---|
| default for all languages | ID_327350590 |
||
| English | Rippling muscle disease with myasthenia gravis |
Immune-mediated rippling muscle disease (iRMD) may concomitantly occur with Acetylcholine receptor positive Myasthenia Gravis (MG) without germline caveolin-3 gene mutations. Acetylcholinesterase-inhibitors may aggravate the symptoms. generalised MG and iRMD are treatable by immunomodulating and immunosuppressant drugs such as prednisone or azathioprine with timely and enduring relief. |
Statements
CID11:ID_327350590
0 references
dki-india-ID_327350590
0 references
Concluído
0 references
13 August 2026
0 references
